{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:28:17Z","timestamp":1792801697466,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","hpbonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["HPB"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hpb.2025.12.018","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:49:14Z","timestamp":1765871354000},"page":"447-462","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6159-1068","authenticated-orcid":false,"given":"Shahin","family":"Hajibandeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3294-4335","authenticated-orcid":false,"given":"Shahab","family":"Hajibandeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3052-7527","authenticated-orcid":false,"given":"Syed S.","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8564-9420","authenticated-orcid":false,"given":"David C.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby V.M.","family":"Dasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Chatzizacharias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Marudanayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith J.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hpb.2025.12.018_bib1","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.hpb.2025.12.018_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.6004\/jnccn.2017.0131","article-title":"Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Tempero","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.hpb.2025.12.018_bib3","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.surg.2012.05.020","article-title":"Pancreatic ductal adenocarcinoma: long term survival does not equal cure","volume":"152","author":"Ferrone","year":"2012","journal-title":"Surgery"},{"key":"10.1016\/j.hpb.2025.12.018_bib4","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s11605-007-0384-8","article-title":"Pancreatic adenocarcinoma: the actual 5-year survivors","volume":"12","author":"Ferrone","year":"2008","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1007\/s00268-015-3353-5","article-title":"Original scientific reports: clinicopathological findings of remnant pancreatic cancers in survivors following curative resections of pancreatic cancers","volume":"40","author":"Suzuki","year":"2016","journal-title":"World J Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib6","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.surg.2023.11.027","article-title":"Meta-analysis of adjuvant chemotherapy versus no adjuvant chemotherapy for resected stage I pancreatic cancer","volume":"175","author":"Evans","year":"2024","journal-title":"Surgery"},{"key":"10.1016\/j.hpb.2025.12.018_bib7","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1002\/cam4.921","article-title":"The use of adjuvant chemotherapy for pancreatic cancer varies widely between hospitals: a nationwide population-based analysis","volume":"5","author":"Bakens","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.hpb.2025.12.018_bib8","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib10","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hpb.2025.12.018_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9041129","article-title":"Neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomized controlled trials","volume":"9","author":"Cloyd","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.hpb.2025.12.018_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2025.12.018_bib13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamasurg.2024.0419","article-title":"Total neoadjuvant therapy for pancreatic cancer-what is totality?","volume":"159","author":"Cannas","year":"2024","journal-title":"JAMA Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12957-017-1240-2","article-title":"Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients","volume":"15","author":"Dhir","year":"2017","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.018_bib15","article-title":"Failure to undergo resection following neoadjuvant therapy for resectable pancreatic cancer: a secondary analysis of SWOG S1505","volume":"22","author":"Cloyd","year":"2024","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.hpb.2025.12.018_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.hpb.2025.12.018_bib17","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.12.018_bib18","unstructured":"J.P.T. Higgins, J. Thomas, J. Chandler, Cumpston M, Li T, Page MJ, Welch VA, Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020), 2020, Cochrane, Available from: www.training.cochrane.org\/handbook (Accessed 5 April 2025), Last accessed."},{"key":"10.1016\/j.hpb.2025.12.018_bib19","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1245\/s10434-007-9384-x","article-title":"A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin","volume":"14","author":"Palmer","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.018_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1002\/jso.21527","article-title":"Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma","volume":"101","author":"Landry","year":"2010","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.018_bib21","first-page":"2377","article-title":"A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer","volume":"34","author":"Sahora","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.hpb.2025.12.018_bib22","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s11605-015-2890-4","article-title":"Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer: a single-center prospective, randomized, controlled trial which failed to achieve accrual targets","volume":"19","author":"Casadei","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","article-title":"Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial","volume":"191","author":"Golcher","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.hpb.2025.12.018_bib24","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2468-1253(18)30081-5","article-title":"Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial","volume":"3","author":"Reni","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2025.12.018_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2018.07.007","article-title":"A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma","volume":"102","author":"Reni","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hpb.2025.12.018_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2019-000668","article-title":"Gemcitabine\/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer","volume":"5","author":"Picozzi","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.hpb.2025.12.018_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00066-020-01680-2","article-title":"R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007\u00b1 trial","volume":"197","author":"Fietkau","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.hpb.2025.12.018_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2468-1253(20)30330-7","volume":"6","author":"Kunzmann","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.hpb.2025.12.018_bib29","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/SLA.0000000000004669","article-title":"A phase 3 randomized clinical trial of chemotherapy with or without Algenpantucel-L (HyperAcute-Pancreas) immunotherapy in subjects with borderline resectable or locally advanced unresectable pancreatic cancer","volume":"275","author":"Hewitt","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","article-title":"Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group","volume":"34","author":"Seufferlein","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hpb.2025.12.018_bib31","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/SLA.0000000000004313","article-title":"Surgical complications in a multicenter randomized trial comparing preoperative chemoradiotherapy and immediate surgery in patients with resectable and borderline resectable pancreatic cancer (PREOPANC trial)","volume":"275","author":"van Dongen","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib32","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/SLA.0000000000005430","article-title":"Results of a phase II study on the use of neoadjuvant chemotherapy (FOLFIRINOX or GEM\/nab-PTX) for borderline-resectable pancreatic cancer (NUPAT-01)","volume":"275","author":"Yamaguchi","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib33","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.hpb.2025.12.018_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007586","article-title":"Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma","volume":"11","author":"Katz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.hpb.2025.12.018_bib35","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/jhbp.1353","article-title":"Randomized phase II trial of chemoradiotherapy with S-1 versus combination chemotherapy with gemcitabine and S-1 as neoadjuvant treatment for resectable pancreatic cancer (JASPAC 04)","volume":"30","author":"Sugiura","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.hpb.2025.12.018_bib36","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1245\/s10434-024-15199-8","article-title":"Results of a randomized clinical study of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable and borderline resectable pancreatic ductal adenocarcinoma (RCT, CSGO-HBP-015)","volume":"31","author":"Yamada","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hpb.2025.12.018_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.hpb.2025.12.018_bib38","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial","volume":"283","author":"Unno","year":"2026","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib39","doi-asserted-by":"crossref","first-page":"zraf007","DOI":"10.1093\/bjsopen\/zraf007","article-title":"Relationship between pancreatic cancer resection rate and survival at population level: systematic review","volume":"9","author":"Lockie","year":"2025","journal-title":"BJS Open"},{"key":"10.1016\/j.hpb.2025.12.018_bib40","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/bjs\/znac354","article-title":"Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis","volume":"110","author":"Brown","year":"2022","journal-title":"Br J Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib41","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/jnci\/djae294","article-title":"Prognostic factors in localized pancreatic ductal adenocarcinoma after neoadjuvant therapy and resection: a systematic review and meta-analysis","volume":"117","author":"Javed","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hpb.2025.12.018_bib42","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1097\/SLA.0000000000006650","article-title":"Validation of the PANAMA score for survival and benefit of adjuvant therapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX","volume":"281","author":"Rompen","year":"2025","journal-title":"Ann Surg"},{"key":"10.1016\/j.hpb.2025.12.018_bib43","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djz073","article-title":"Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"111","author":"Janssen","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.hpb.2025.12.018_bib44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1097\/MPA.0000000000002147","article-title":"Defining the optimal duration of neoadjuvant therapy for pancreatic ductal adenocarcinoma: time for a personalized approach?","volume":"51","author":"Puleo","year":"2022","journal-title":"Pancreas"},{"key":"10.1016\/j.hpb.2025.12.018_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(25)01685-X","article-title":"Preoperative mFOLFIRINOX versus PAXG for stage I-III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2 \u00d7 2 factorial phase 3 trial","author":"Reni","year":"2025","journal-title":"Lancet"}],"container-title":["HPB"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25017320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1365182X25017320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T09:23:14Z","timestamp":1775121794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1365182X25017320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1365182X25017320"],"URL":"https:\/\/doi.org\/10.1016\/j.hpb.2025.12.018","relation":{},"ISSN":["1365-182X"],"issn-type":[{"value":"1365-182X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of duration of neoadjuvant therapy on pancreatic cancer outcomes: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"HPB","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hpb.2025.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}